Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

Trial Details

NCT ID

NCT07093073

Phase

PHASE1

Sponsor

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• ssCART-19

Locations (sample)

• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• Voluntary written informed consent obtained from the participant (or legal guardian) with good compliance expected throughout the study.
• All of the following conditions must be met:
• Age 2-75 years at informed consent; both sexes eligible. For minors (≤18 years), consent must be provided by a parent/legal guardian; minors able t…
• Histologically confirmed B-cell lymphoma per the 2024 v3 NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.